Your browser doesn't support javascript.
Preliminary evidence of blunted humoral response to SARS-CoV-2 mRNA vaccine in multiple sclerosis patients treated with ocrelizumab.
Gallo, Antonio; Capuano, Rocco; Donnarumma, Giovanna; Bisecco, Alvino; Grimaldi, Elena; Conte, Miriana; d'Ambrosio, Alessandro; Coppola, Nicola; Galdiero, Massimiliano; Tedeschi, Gioacchino.
  • Gallo A; Department of Advanced Medical and Surgical Sciences, University of Campania "Luigi Vanvitelli", Naples, Italy. antonio.gallo@unicampania.it.
  • Capuano R; Department of Advanced Medical and Surgical Sciences, University of Campania "Luigi Vanvitelli", Naples, Italy.
  • Donnarumma G; Department of Experimental Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy.
  • Bisecco A; Department of Advanced Medical and Surgical Sciences, University of Campania "Luigi Vanvitelli", Naples, Italy.
  • Grimaldi E; Department of Experimental Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy.
  • Conte M; Department of Advanced Medical and Surgical Sciences, University of Campania "Luigi Vanvitelli", Naples, Italy.
  • d'Ambrosio A; Department of Advanced Medical and Surgical Sciences, University of Campania "Luigi Vanvitelli", Naples, Italy.
  • Coppola N; Department of Mental Health and Public Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy.
  • Galdiero M; Department of Experimental Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy.
  • Tedeschi G; Department of Advanced Medical and Surgical Sciences, University of Campania "Luigi Vanvitelli", Naples, Italy.
Neurol Sci ; 42(9): 3523-3526, 2021 Sep.
Article in English | MEDLINE | ID: covidwho-1269165
Semantic information from SemMedBD (by NLM)
1. Multiple Sclerosis PROCESS_OF Patients
Subject
Multiple Sclerosis
Predicate
PROCESS_OF
Object
Patients
2. ocrelizumab TREATS Multiple Sclerosis
Subject
ocrelizumab
Predicate
TREATS
Object
Multiple Sclerosis
3. ocrelizumab TREATS Responsive Disease
Subject
ocrelizumab
Predicate
TREATS
Object
Responsive Disease
4. ocrelizumab TREATS Patients
Subject
ocrelizumab
Predicate
TREATS
Object
Patients
5. Responsive Disease PROCESS_OF Patients
Subject
Responsive Disease
Predicate
PROCESS_OF
Object
Patients
6. COVID-19 Vaccines ASSOCIATED_WITH Multiple Sclerosis
Subject
COVID-19 Vaccines
Predicate
ASSOCIATED_WITH
Object
Multiple Sclerosis
7. Responsive Disease COEXISTS_WITH Multiple Sclerosis
Subject
Responsive Disease
Predicate
COEXISTS_WITH
Object
Multiple Sclerosis
8. Vaccines ASSOCIATED_WITH Multiple Sclerosis
Subject
Vaccines
Predicate
ASSOCIATED_WITH
Object
Multiple Sclerosis
9. Multiple Sclerosis PROCESS_OF Patients
Subject
Multiple Sclerosis
Predicate
PROCESS_OF
Object
Patients
10. ocrelizumab TREATS Multiple Sclerosis
Subject
ocrelizumab
Predicate
TREATS
Object
Multiple Sclerosis
11. ocrelizumab TREATS Responsive Disease
Subject
ocrelizumab
Predicate
TREATS
Object
Responsive Disease
12. ocrelizumab TREATS Patients
Subject
ocrelizumab
Predicate
TREATS
Object
Patients
13. Responsive Disease PROCESS_OF Patients
Subject
Responsive Disease
Predicate
PROCESS_OF
Object
Patients
14. COVID-19 Vaccines ASSOCIATED_WITH Multiple Sclerosis
Subject
COVID-19 Vaccines
Predicate
ASSOCIATED_WITH
Object
Multiple Sclerosis
15. Responsive Disease COEXISTS_WITH Multiple Sclerosis
Subject
Responsive Disease
Predicate
COEXISTS_WITH
Object
Multiple Sclerosis
16. Vaccines ASSOCIATED_WITH Multiple Sclerosis
Subject
Vaccines
Predicate
ASSOCIATED_WITH
Object
Multiple Sclerosis
ABSTRACT

OBJECTIVES:

Several concerns regard the immunogenicity of SARS-CoV-2 vaccines in people with multiple sclerosis (pwMS), since the majority of them is treated with immunomodulating/immunosuppressive disease modifying therapies. Here we report the first data on the humoral response to mRNA SARS-CoV-2 vaccine in a case series of 4 pwMS treated with ocrelizumab (OCR) as compared to a group of healthy subjects (HS).

METHODS:

We collected serum samples at 0, 14, 21 days after the first dose and 7 days after the second dose of BNT162b2-mRNA-Covid-19 vaccine from 55 health-care workers and 4 relapsing pwMS on OCR, with no history of Covid-19 infection. Sera were tested using the LIAISON®SARS-CoV-2 TrimericS-IgG assay (DiaSorin-S.p.A.) for the detection of IgG antibodies to SARS-CoV-2 spike protein. The anti-spike IgGtiters were expressed in Binding Antibody Units (BAU), an international standard unit.

RESULTS:

At baseline all subjects were negative for anti-spike IgG. Seven days after the second dose of vaccine all HS mounted a significant humoral response (geometric mean 2010.4 BAU/mL C.I. 95% 1512.7-2672) while the 4 pwMS showed a lower response (range <4.81-175 BAU/mL).

DISCUSSION:

Humoral response to BNT162b2-mRNA-vaccine in pwMS treated with OCR was clearly blunted. Further data are urgently needed to confirm and expand these preliminary results and to develop strategies to optimize the response to SARSCoV-2 vaccines in pwMS on OCR.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 / Multiple Sclerosis Type of study: Prognostic study Topics: Vaccines Limits: Humans Language: English Journal: Neurol Sci Journal subject: Neurology Year: 2021 Document Type: Article Affiliation country: S10072-021-05397-7

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 / Multiple Sclerosis Type of study: Prognostic study Topics: Vaccines Limits: Humans Language: English Journal: Neurol Sci Journal subject: Neurology Year: 2021 Document Type: Article Affiliation country: S10072-021-05397-7